Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center

BACKGROUND: Poor-risk advanced Renal cell carcinoma (RCC) are an under-evaluated and difficult to treat subset of patients with poor prognosis. While Temsirolimus is the approved first line therapy for this category, Tyrosine kinase inhibitors (TKIs) are also commonly uses as initial treatment. We p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramaswamy, Anant, Joshi, Amit, Noronha, Vanita, Patil, Vijay, Sahu, Arvind, Manickam, Deepan R, Kothari, Rushabh, Sable, Nilesh, Agrawal, Archi, Menon, Santosh, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686973/
https://www.ncbi.nlm.nih.gov/pubmed/29200680
http://dx.doi.org/10.4103/ijmpo.ijmpo_154_16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686973/
https://www.ncbi.nlm.nih.gov/pubmed/29200680
http://dx.doi.org/10.4103/ijmpo.ijmpo_154_16

Ejemplares similares